================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) July 25, 2006
PHARMION CORPORATION
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-50447 84-1521333
---------------------------- ---------------- -------------------
(State or other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
2525 28th Street, Boulder, Colorado 80301
---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 720-564-9100
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
----
On July 25, 2006, Pharmion Corporation issued a press
release describing the financial results of the Company for the
quarter ended June 30, 2006. A copy of the press release is
attached as Exhibit 99.1 and is being incorporated herein by
reference.
The information incorporated by reference in Item 2.02 of
this Form 8-K and Exhibit 99.1 attached hereto shall not be
deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934 (the "Exchange Act") or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, regardless of any general
incorporation language in such filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
----
(d) Exhibits
EXHIBIT
NUMBER DESCRIPTION
-------- -----------------------------------------------------
99.1 Press Release, dated July 25, 2006.
This exhibit is furnished pursuant to Item 2.02 and
shall not be deemed to be "filed."
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMION CORPORATION
Date: July 25, 2006 By: /s/ Erle T. Mast
------------------------
Name: Erle T. Mast
Title: Chief Financial Officer